PHCP 403 by L. K. Sarki
|
|
- Cecil Hugh Reynolds
- 5 years ago
- Views:
Transcription
1 PHCP 403 by L. K. Sarki
2 objectives To gain insight into the epidemiology of HIV To gain basic understanding of the etiology of HIV disease To know the clinical manifestations of the disease To gain a basic understanding of the treatment of HIV disease To be aware of the complexities of treatment
3 What does it stand for? HIV Human Immunodeficiency Virus Causes a gradual decline in immune function by destroying CD4 immune helper cells AIDS Acquired Immunodeficiency Syndrome Diagnosed when the patient suffers one a list of AIDS defining illness
4 First reports: MMWR 1981 MMWR report on pneumocystis pneumonia in live previously healthy young men in Los Angeles-June Kaposis s and pneumocystis pneumonia among homosexual men-new York and California
5 Early history of AIDS July 81: Jan 82: July 82: Dec 82: Infections noted in haemophiliacs, Haitians Syndrome termed GRID CDC defines AIDS 4 cases of unexplained immune deficiency in infants reported (MMWR)
6 Early history of AIDS Jan 83: May 83: April 84: Aug 84: May 86: First screening of high risk blood donors Pasteur institute report lymphadenopathy virus (LAV) Discovery of AIDS virus (HTLV-III) by Robert Gallo announced in USA First commercial AIDS test Virus remained HIV
7 Evolving therapy management : Treatment of opportunistic diseases and symptoms only 1987: First antiretroviral (ZDV) licensed : Availability of other NRTIs (ddi) : Dual combination therapy (2 NRTIs) 1995: Quantification of HIV load by PCR
8 Evolving therapy management 1995: First HIV protease inhibitor and introduction of HAART 1996: Non-nucleoside RT inhibitors (NNRTIs) 1998: Realization of the difficulty (impossibility?) of eradicating HIV 1998: Resistance testing 2000: PI boosting 2001: Therapeutic drug monitoring
9 Global summary of the AIDS epidemic 2013 Number of people Total living with HIV in 2013 Adults Women Children (<15 years) People newly infected with HIV in 2013 Total Adults Children (<15 years) 35.0 million [33.1 million 37.2 million] 31.8 million [30.1 million 33.7 million] 16.0 million [15.2 million 16.9 million] 3.2 million [2.9 million 3.5 million] 2.1 million [1.9 million 2.4 million] 1.9 million [1.7 million 2.1 million] [ ] AIDS deaths in 2013 Total Adults Children (<15 years) 1.5 million [1.4 million 1.7 million] 1.3 million [1.2 million 1.5 million] [ ]
10 Adults and children estimated to be living with HIV 2013 North America and Western and Central Europe 2.3 million Caribbean [ ] [2.0 million 3.0 million] Latin America 1.6 million [1.4 million 2.1 million] Middle East & North Africa [ ] Sub-Saharan Africa 24.7 million [23.5 million 26.1 million] Eastern Europe & Central Asia 1.1 million [ million] Asia and the Pacific 4.8 million [4.1 million 5.5 million] Total: 35.0 million [33.2 million 37.2 million]
11 Estimated number of adults and children newly infected with HIV 2013 North America and Western and Central Europe [ ] Caribbean [ ] Latin America [ ] Middle East & North Africa [ ] Sub-Saharan Africa 1.5 million [1.3 million 1.6 million] Eastern Europe & Central Asia [ ] Asia and the Pacific [ ] Total: 2.1 million [1.9 million 2.4 million]
12 Estimated adult and child deaths from AIDS 2013 North America and Western and Central Europe [ ] Caribbean [ ] Latin America [ ] Middle East & North Africa [ ] Sub-Saharan Africa 1.1 million [1.0 million 1.3 million] Eastern Europe & Central Asia [ ] Asia and the Pacific [ ] Total: 1.5 million [1.4 million 1.7 million]
13 About new HIV infections a day in 2013 About 68% are in Sub Saharan Africa About 700 are in children under 15 years of age About are in adults aged 15 years and older, of whom: almost 47% are among women about 33% are among young people (15-24)
14
15 Epidemiology of HIV in Nigeria: Key Facts National Median HIV Prevalence 4.6% 4.1% Estimated Number of PLWHIV 2,980,000 3,459,363 Annual AIDS Death 192, ,148 Number requiring Antiretroviral Therapy 857,455 1,449,166 New HIV Infections 336, ,864 Total Number of AIDS Orphans 2,175,760 2,193,745
16 Transmission Infection can be acquired through 4 main routes Unprotected sexual intercourse (vaginal or anal) About 85% of all infections Sharing needles Injectable drug use Needlesticks from HIV infected patients» Usually healthcare workers Transfusions Vertical transmission from mother to child Prenatal infection breastfeeding
17 pathogenesis CD4 is a receptor on the white blood cells HIV uses (binds) the CD4 receptor to infect cells Once bound to the CD4 Coreceptors CCR-5 CXCR-4 Are required for fusion
18 pathogenesis HIV fuses with the cell releasing its single-stranded RNA in addition to other specific enzymes into the host cell Single-stranded viral RNA is then transcribed by reverse transcriptase into a double-stranded proviral DNA Proviral DNA is then incoporated into the host cell s genetic material through the integrase enzyme
19 pathogenesis HIV then uses the infected host cell s machinery to translate, transcribe and produce immature virions made infectious with the help protease enzymes bud and break from the host cell Mature virion becomes free to infect new host cells and subsequently produce more infectious virus
20
21 pathogenesis Destruction of the existing and inhibition of the formation of new CD4 cells Transient depletion of CD4 cells occurs Places the host at an increased risk for opportunistic infections Initially, patients may complain of nonspecific symptoms acute retroviral syndrome Fever, lymphadenopathy, fatigue and night sweats
22
23 CD4 count CD4 count used as a marker of immune function The lower the CD4 the less efficient the immune system Low CD4 (<200 cells/mm 3 ) puts patients at risk of opportunistic infections
24 Clinical manifestations Opportunistic infections Rare in otherwise healthy immunocompetent individuals due to intact cell-mediated immunity against infections Immunosuppresed individuals HIV Shingle (herpes zoster) Oral thrush Anaemia, weight loss Recurrent candidal vaginal infections Active tuberculosis
25 Clinical manifestations In more advanced cases- CD4 <200cells/mm 3 Tuberculosis Oesophageal candida Pneumocyctis jiroveci pneumonia Toxoplasmosis Kaposi s sarcoma Cryptococcal meningitis Severely depressed immune system CD4 75 cells/mm 3 Dessiminated CMV
26
27 Testing for HIV ELISA based test- antibody based test Highly sensitive & specific Represent a good screening test But 3 months window till positive Same day testing now available Walk in clinic Finger prick test Result available in 10 to 15 minutes
28 Viral load (VL) The amount of virus in 1 millilitre of blood Without treatment VL from million copies/ml Aim of treatment to become undetectable (VL <50 cps/ml) An undetectable VL reduces amount of replication of virus, and reduces chance of resistance to antiretroviral drugs
29 When to treat HIV disease stage CD4 count(cells/mm 3 ) Recommendation Early (primary) infection Any CD4 level Treatment in clinical trial; or neurological involvement; AIDS-defining illness; or CD4 <200cells/mm 3 >3/12 Established (chronic) infection without symptoms CD4 >500 CD CD CD4 < 200 Consider enrolment into when to start trial Treat in specific situations with higher risk of clinical events AIDS diagnosis (except TB); HBV; HCV; CVD Treat ASAP when patient ready Start treatment Established (chronic) infection with symptoms Any CD4 count Start treatment (except for TB when CD4 >350cells/mm 3 ) pregnancy Any CD4 count Use hospital/national/international pregnancy guidelines HIV- associated nephropathy (HIVAN) Any CD4 count Start but consider renal elimination of ARVs, in particular NRTIs
30 Available ARVs NRTIs: Abacavir Didanosine Emtricitabin e Lamivudine Stavudine Tenoforvir Zidovudine NNRTIs Efavirenz Nevirapine Etravirine Protease inhibitors: Atazanavir Darunavir Amprenavir Indinavir Lopinavir Nelfinavir Ritonavir Saquinavir New Classes Fusion inhibition: Enfuvirtide R5 inhibitors: Maraviroc Integrase inhibitors: Raltegravir
31 Highly active antiretroviral therapy (HAART) Most evidence for: 2 NRTIs + NNRTI (regimen of choice) Alternatively 2 NRTIs + boosted PI
32 What to treat with Drug 1 Drug 2 Drug 3 Preferred: Tenoforvir ع : or و Abacavir Alternative: zidovudine لا : or Didanosin لا,و Lamivudine Or ع emtricitabin Preferred: ع Efavirenz Alternative kaletra others Specific groups ق Nevirapine Tenoforvirع and Emtricitabin available as the co-formulated Truvada and in combination with efavirenz as Atripla Abacavir and Lamivudine available as the co-formulated Kivexa و Zidovudine and Lamivudine available as the co-formulated Combivir لا Nevirapine should be avoided in women with CD4 >250 cells/mm3 and males with CD4 ق >400cells/mm3 due to significantly increased risk of hepatitis and severe rash
33 Adherence affects clinical outcome 95% adherence is required to achieve undetectable viral load Reasons for poor adherence include: Side effects Disclosure Stigma Too complicated Reminder of illness Don t remember
34 toxicities Zidovudine Anaemia (esp with combivir as AZT 300mg bd) Tenoforvir Concerns over renal safety Nevirapine Hepatotoxicity Remember CD4 cut off for Rx rash
35 toxicities Abacavir Hypersensitivity in 5 7% of patients Characterised as rash, or 2 of the following: Fever Shortness of breath, or sore throat or cough Nausea, vomiting, diarrhoea or abdominal pain Severe tiredness or achiness, or generally ill feeling NB: genet link: HLAB*5701
36 toxicities Efavirenz CNS disturbances (concern if Hx of depression) Not advised if considering pregnancy Preferred NNRTI
37 atripla Tenoforvir 300mg Emtricitabine 200mg Efavirenz 600mg One pill once a day
38 Cytochrome P450 Induction/inhibition of CYP3A4 can influence drug metabolism NNRTI/rifampicin induce CYP3A4 Ritonavir inhibits CYP3A4 Retonavir used as PK booster for other PIs
39 statins Drug (metabolism) NNRTI PI (boosted) Simvastatin (CYP3A4, 2D6, 2C9) Fluvastatin (CYP2C9>>3A4) Atorvastatin (CYP3A4) 60% AUC simva Advice: avoid!!! No sig. interaction Rx as normal 40% atorva levels. Start at 20mg and titrate x AUC simva Advice: avoid!!! No sig. interaction Rx as normal but may see more s/e at max dose 4 6x atorva levels. Advice: start with 10mg od and titrate. Usual max 20mg od.others? Check an don t assume
40 Anti epileptics Drug (metabolism) NNRTI PI (boosted) Phenytoin (CYP2C9) Carbamazepine (CYP3A4) 30% in both phenytoin and NNRTI levels. Advice: AVOID for chronic care carb levels NNRTI levels Advice: AVOID 30% in both phenytoin and PI levels. Advice: AVOID for chronic care 50% carb levels & PI levels. Advice: AVOID.Others? Check an don t assume
41 HIV & pregnancy Not a contraindication and not discouraged National antenatal screening Actions: Initiate HAART weeks C-section if VL >50cps/ml Neonate given 4/52 PEP Bottle feed (not breast feeding)
42 Prophylaxis? Post-exposure prophylaxis (PEP) is short-term antiretroviral treatment to reduce the likelihood of HIV infection after potential exposure, either occupationally or through sexual intercourse 28 day course ART Vaccine?
HIV and AIDS An update
HIV and AIDS An update Barnet branch 24 th February 2009 Neal Marshall Specialist pharmacist HIV services Royal Free Hampstead NHS Trust Objectives To gain an insight into the epidemiology of HIV To gain
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationHuman Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS
Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s
More informationHIV in Obstetrics and Gynecology
FAST FACTS HIV in Obstetrics and Gynecology Indispensable Guides to Clinical by J Richard Smith, Naomi Low-Beer and Bruce A Barron Practice HIV infection 7 Managing infected women 13 Preconceptual care
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationINITIATING ART IN CHILDREN: Follow the six steps
INITIATING ART IN CHILDREN: Follow the six steps STEP 1: DECIDE IF THE CHILD HAS CONFIRMED HIV INFECTION Child < 18 months: HIV infection is confirmed if the PCR is positive and the VL is more than 10,000
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationThe Global HIV Epidemic. Jerome Larkin, MD
The Global HIV Epidemic Jerome Larkin, MD Outline Global Epidemiology Natural History of HIV Antiretroviral Therapy Malaria Tuberculosis Prevention of Mother to Child Transmission Post-Exposure Prophylaxis
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationImproving accessibility to antiretroviral drugs: A south-south collaboration
Improving accessibility to antiretroviral drugs: A south-south collaboration Jaideep A Gogtay MD Cipla Ltd Mumbai jgogtay@cipla.com Adults and children estimated to be living with HIV at the end of 2000
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital
HIV Lecture Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital End-2001 global estimates for children and adults People living with HIV/AIDS New HIV infections in
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationBlood-Borne Pathogens and Post-Exposure Prophylaxis
Blood-Borne Pathogens and Post-Exposure Prophylaxis Christopher Behrens MD Northwest Association of Occupational and Environmental Medicine October 2017 with thanks to Shireesha Dhanireddy MD Disclosures
More informationHIV Clinical Nurse Specialist CCDHB Wellington
RN James Rice-Davies HIV Clinical Nurse Specialist CCDHB Wellington 11:00-11:55 WS #88: Undiagnosed HIV in Your Practice 12:05-13:00 WS #99: Undiagnosed HIV in Your Practice (Repeated) HIV- Undiagnosed
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationWhat we will cover. HIV in Case 1. HIV drugs frequently cause drug reactions. What is the most likely diagnosis
HIV in 2009 Susan Hopkins Consultant in Infectious Diseases & Microbiology Royal Free Hampstead NHS Trust What we will cover Not Opportunistic Infections Important adverse events Important points to consider
More informationPreventing Mother to Child HIV Transmission: Are We There Yet?!'
Preventing Mother to Child HIV Transmission: Are We There Yet?!' 2017 Michigan Clincal Nursing Conference for HIV and STD Care May 18, 2017 Frankenmuth MI 1 Theodore B. Jones, MD Maternal Fetal Medicine
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationHIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED
HIV and PEP LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy of the Department
More information10/17/2015. Chapter 55. Care of the Patient with HIV/AIDS. History of HIV. HIV Modes of Transmission
Chapter 55 Care of the Patient with HIV/AIDS All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. History of HIV Remains somewhat obscure The earlier
More information2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee,
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationCh 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems
Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems Highlight Disease: Malaria World s dominant protozoal disease. Four species of Plasmodium: P. falciparum (malignant), P. vivax (begnin),
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationHIV A 2017 Update Bill Rooney MD SCOR Global Life
NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationBenefits and Risks of ART
Benefits and Risks of ART Dr Paula Munderi WHO Training Course for Introducing Pharmacovigilance of HIV Medicines 23 28 November 2009, Dar Es Salaam Summary Progress in ART coverage WHO Progress Report
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS
ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is
More informationMedical Overview March 7, Nina Lambert, NP Inova Juniper Program
Medical Overview March 7, 2019 Nina Lambert, NP Inova Juniper Program Nina.lambert@inova.org Inova Juniper Program Sites Offering medical care, case management and mental health for youth and adults who
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationModule 1: HIV epidemiology, transmission and prevention
Session 1 Module goals Module 1 Participants will be able to: -offer an insight into the epidemiological situation in the country and worldwide -present the HIV transmission modes and the broad approaches
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationU=U NHIVNA HIV, Fertility and Contraception in the era of
HIV, Fertility and Contraception in the era of U=U NHIVNA 2018 Yvonne Gilleece Consultant in HIV and Sexual Health Brighton &Sussex University Hospitals NHS Trust Honorary Senior Lecturer Brighton & Sussex
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationOverview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research
Overview of HIV Christina Polyak, MD, MPH Research Physician U.S. Military HIV Research Program, Walter Reed Army Institute of Research The views expressed are those of the authors and should not be construed
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationClass Review: HIV Antiretroviral Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationHUMAN IMMUNODEFICIENCY VIRUS (HIV) AND AIDS
HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND AIDS Mohamed Mahdi MD. MPH. Department of Infectology and Pediatric Immunology University of Debrecen (MHSC) 2015 Historical facts about HIV First presentation in
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationHIV Pathology and ART Basics A Review for Non-Prescribing Clinical Staff
HIV Pathology and ART Basics A Review for Non-Prescribing Clinical Staff Dr. Brent J. Pimentel, MD/MPH Texas Program Manager South Central AETC Parkland Health & Hospital System Dallas, TX 1 Objectives
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More informationHIV Update: What the Hospital-Based Provider Should Know
HIV Update: What the Hospital-Based Provider Should Know Steven C. Johnson M.D. Division of Infectious Diseases, University of Colorado School of Medicine October 6, 2011 45 year old female Case Study
More informationPresented by: Melissa Egan, Regional Health Education Coordinator, CATIE Date: Tuesday October 8th, 2013, 1 2pm EST
Presented by: Melissa Egan, Regional Health Education Coordinator, CATIE Date: Tuesday October 8th, 2013, 1 2pm EST Agenda 1. HIV and the immune system 2. The progression of untreated HIV 3. Monitoring
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationmedical monitoring: clinical monitoring and laboratory tests
medical monitoring: clinical monitoring and laboratory tests Purpose of monitoring Check on the physical, psychological and emotional condition of the patient Detect other treatable conditions Identify
More informationWhat does the HIV Pharmacy Team need to know about PEP
What does the HIV Pharmacy Team need to know about PEP Rosy Weston Senior Lead Pharmacist Sexual Health and HIV St. Mary s Hospital Imperial College Healthcare NHS Trust London November 2008 Objectives
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More information